BDTX-1535 is a brain-penetrant and potent MasterKey inhibitor of oncogenic mutations of EGFR, including the mutations that co-occur in GBM, as well as those that commonly occur in NSCLC and those that emerge as resistance mechanisms to current-generation EGFR inhibitors.
For research use only. We do not sell to patients.
| Name | BDTX-1535 |
|---|---|
| Iupac Chemical Name | (2E)-N-[4-[(3-Chloro-2-fluorophenyl)amino]-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hex-1-yl]ethynyl]-6-quinazolinyl]-4-(4-morpholinyl)-2-butenamide |
| Synonyms | BDTX-1535 ; BDTX 1535 ; BDTX1535 ; |
| Molecular Formula | C30H30ClFN6O2 |
| Molecular Weight | 560.2103 |
| Smile | O=C(NC1=CC2=C(NC3=CC=CC(Cl)=C3F)N=CN=C2C=C1C#C[C@]45CN(C)C[C@@]4([H])C5)/C=C/CN6CCOCC6 |
| InChiKey | LMOVDLRMIRLIJF-TUVXKDNKSA-N |
| InChi | InChI=1S/C30H30ClFN6O2/c1-37-17-21-16-30(21,18-37)8-7-20-14-26-22(29(34-19-33-26)36-24-5-2-4-23(31)28(24)32)15-25(20)35-27(39)6-3-9-38-10-12-40-13-11-38/h2-6,14-15,19,21H,9-13,16-18H2,1H3,(H,35,39)(H,33,34,36)/b6-3+/t21-,30+/m1/s1 |
| CAS Number | 2607829-38-7 |
| Related CAS | 2607829-38-7 |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Yellow solid |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
| Targets | EGFR inhibitor |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |